Lumiliximab, also known as ST-152, represents a promising antibody targeting the soluble receptor for interleukin -13. This specific compound demonstrates impressive potential in addressing fibrotic conditions , particularly those involving cardiac failure . Studies indicate that ST-152 successfu

Satralizumab, previously known as SA-237 , represents a exciting treatment for neuromyelitis optica spectrum disorder and other neurological ailments. Latest investigations have demonstrated positive data regarding its

New data suggests that Cilgavimab, formerly known as COV2-2130, demonstrates significant capability as a therapeutic agent against COVID-19. This immunoglobulin exhibits a distinctive method of action , in particular neutralizing the virus's ACE2 interface with considerable strength . Preliminary